A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery (TEXT-TKR)

A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery

The primary purpose of Part 1 in this study is to assess the safety and tolerability of JNJ-64179375 for each dose level for dose escalation and any bleeding events (the composite of major, clinically relevant non-major, and minimal bleeding events) for the selection of doses for Part 2. The primary purpose of Part 2 is to assess the efficacy dose response of JNJ-64179375 for the prevention of total venous thromboembolism (VTE) (proximal and/or distal deep vein thrombosis [DVT] [asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic], nonfatal pulmonary embolism [PE], or any death).

Study Overview

• Status: Completed
• Conditions: VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery
• Intervention / Treatment: Drug: JNJ-64179375 0.3 mg/kg; Drug: Placebo JNJ-64179375; Drug: Apixaban placebo; Drug: Apixaban 2.5 mg; Drug: JNJ-64179375 0.6 mg/kg; Drug: JNJ-64179375 1.2 mg/kg; Drug: JNJ-64179375 (Dose to be Determined); Drug: JNJ-64179375 A mg/kg; Drug: JNJ-64179375 B mg/kg; Drug: JNJ-64179375 C mg/kg; Drug: JNJ-64179375 D mg/kg

Detailed Description

This study has 2 parts, dose escalation and dose-response evaluation, and will be conducted in participants undergoing primary unilateral elective Total Knee Replacement (TKR) surgery. Participants will participate in either Part 1 or Part 2 of study only. The study will be conducted in 3 phases: an up to 30-day screening phase before surgery, a 14-day double-blind dosing phase, and a 16-week follow-up phase. Safety evaluations will include monitoring of all nonserious and serious adverse events, clinical laboratory tests, vital signs measurements, and physical examinations. Pharmacokinetics (dense and sparse), pharmacodynamic (PD), health resource utilization, and immunogenicity samples will also be assessed. The total study duration of participant's participation in Part 1 or part 2 after randomization will be approximately 18 weeks.

• Study Type: Interventional
• Enrollment (Actual): 308
• Phase: Phase 2

Contacts and Locations

Study Locations

• Argentina
  • Caba, Argentina, C1199ABB
    • Hospital Italiano de Buenos Aires
  • Caba, Argentina, C1430EGF
    • Clinica Adventista Belgrano
  • Córdoba, Argentina, 5000
    • Hospital San Roque
  • Córdoba, Argentina, X5000EPU
    • Clínica Chutro
  • La Plata, Argentina, B1900AXI
    • Hospital Italiano La Plata
  • Rosario, Argentina, 2000
    • Sanatorio Británico de Rosario
  • San Miguel, Argentina, B1663GFL
    • Sanatorio San Miguel
• Belgium
  • Antwerpen, Belgium, 2020
    • ZNA Middelheim
  • Genk, Belgium, 3600
    • Ziekenhuis Oost-Limburg
  • Hasselt, Belgium, 3500
    • Jessa Ziekenhuis
  • Merksem, Belgium, 2170
    • ZNA Jan Palfijn
• Brazil
  • Belo Horizonte, Brazil, 30130-100
    • Universidade Federal de Minas Gerais (UFMG) - Faculdade de Medicina
  • Belo Horizonte, Brazil, 30360-290
    • Hospital Sao Francisco de Assis
  • Campinas, Brazil, 13083-888
    • Unicamp - Hospital de Clinicas
  • Londrina, Brazil, 86050-000
    • Uniort.e - Hospital de ortopedia
  • Marilia, Brazil, 17515-000
    • Irmandade da Santa Casa de Misericórdia de Marília
  • Porto Alegre, Brazil, 90020-090
    • Santa Casa de Misericórdia de Porto Alegre
  • Santo André, Brazil, 09030-010
    • Hospital e Maternidade Dr Christóvão da Gama
  • Santo André, Brazil, 09190-615
    • Hospital Estadual Mario Covas
  • São Paulo, Brazil, 05403-010
    • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo
• Bulgaria
  • Russe, Bulgaria, 7002
    • Multiprofile Hospital for Active Treatment Russe
  • Sofa, Bulgaria, 1407
    • Acibadem City Clinic Tokuda Hospital
  • Sofia, Bulgaria, 1606
    • Military Medical Academy
• Canada
  • Ontario
    • Ajax, Ontario, Canada, L1S 2J4
      • Lakeridge Health Ajax
    • Kitchener, Ontario, Canada, N2M 1A1
      • Source Trial Solutions Inc.
    • Ottawa, Ontario, Canada, K1H 8L6
      • The Ottawa Hospital Research Institute
• Italy
  • Bergamo, Italy, 24127
    • Azienda Ospedaliera Papa Giovanni XXIII
  • Bergamo, Italy, 24125
    • Cliniche Humanitas Gavazzeni
  • Bologna, Italy, 40136
    • Istituto Ortopedico Rizzoli
  • Firenze, Italy, 50134
    • Azienda Ospedaliera Universitaria Careggi
  • Rozzano, Italy, 20089
    • Istituto Clinico Humanitas
  • S. Donato Milanese, Italy, 20097
    • IRCCS Policlinico San Donato
  • Torino, Italy, 10126
    • A.O.U. Città della Salute e della Scienza
  • Torino, Italy, 10128
    • Ospedale Mauriziano (Torino)
• Japan
  • Chiba, Japan, 270-2296
    • Matsudo City General Hospital
  • Hakodate, Japan, 040-8611
    • Hakodate Goryokaku Hospital
  • Iida-shi, Japan, 395-8505
    • Ritsuzankai Iida Hospital
  • Itami-shi, Japan, 664-8540
    • Itami City Hospital
  • Kagoshima-shi, Japan, 890-0062
    • Yonemori Hospital
  • Kawanuma-Gun, Japan, 969-6593
    • Bange Kousei General Hospital
  • Osaka, Japan, 591-8025
    • Osaka Rosai Hospital
  • Osaka-shi, Japan, 530-0012
    • Osaka Saiseikai Nakatsu Hospital
  • Tokushima-shi, Japan, 770-0812
    • Tokushima Municipal Hospital
  • Tomishiro, Japan, 901-0243
    • Yuaikai Tomishiro Central Hospital
• Latvia
  • Liepaja, Latvia, LV-3414
    • Regional Hospital of Liepaja
  • Riga, Latvia, LV1004
    • Riga 2nd Hospital
  • Riga, Latvia, LV1005
    • Hospital of Traumatology and Orthopedics
  • Valmiera, Latvia, LV-4201
    • Vidzemes Hospital
• Lithuania
  • Kaunas, Lithuania, LT50161
    • Hospital of Lithuanian University of Health Sciences Kaunas Clinics
  • Klaipeda, Lithuania, 92288
    • Klaipeda university hospital
• Malaysia
  • Kuala Lumpur, Malaysia, 59100
    • University Malaya Medical Center
  • Kuantan, Malaysia, 25100
    • Hospital Tengku Ampuan Afzan
  • Miri, Malaysia, 98000
    • Hospital Miri
  • Sibu, Malaysia, 96000
    • Hospital Sibu
  • Sungai Petani, Malaysia, 08000
    • Hospital Sultan Abdul Halim
• Poland
  • Bialystok, Poland, 15-276
    • Klinika Ortopedii i Traumatologii UMB
  • Grajewo, Poland, 19-203
    • Oddzial Ortopedii i Traumatologii - Szpital Ogolny im. W.Ginela
  • Katowice, Poland, 40-635
    • Klinika Ortopedii Gornoslaskie Centrum Medyczne
  • Krakow, Poland, 31-826
    • Oddzial Ortopedii i Traumatologii Szpital Specjalistyczny im. L.Rydygiera
  • Krakow, Poland, 33-332
    • SP ZOZ MSWiA w Krakowie Oddzial Urazowo-Ortopedyczny
  • Lodz, Poland, 92-213
    • CSK UM Klinika Ortopedii
  • Lublin, Poland, 20-718
    • Oddzial Urazowo-Ortopedyczny Wojewodzki Szpital Specjalistyczny
  • Poznan, Poland, 61-545
    • Klinika Ortopedii I Traumatologii,Szpital Kliniczny Ortopedyczno-Rehabilitacyjny UM
  • Tarnow, Poland, 33-100
    • Oddzial Ortopedii Specjalistyczny Szpital im. E.Szczeklika
  • Warszawa, Poland, 03-242
    • Oddzial Chirurgii Urazowej iOrtopedycznej,Wojewodzki Szpital Brodnowski, SPZOZ
• Russian Federation
  • Barnaul, Russian Federation, 656045
    • Barnaul Federal Center of Traumatology, Orthopedics and Endoprothesis replacement
  • Kurgan, Russian Federation, 640014
    • Russian Ilizarov Scientific Center For Restorative Traumatology And Ortopaedics
  • Moscow, Russian Federation, 117049
    • Moscow City Clinical Hospital #1 n.a. N.I.Pirogov
  • Nizhny Novgorod, Russian Federation, 603155
    • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
  • Saint-Petersburg, Russian Federation, 194354
    • St. Petersburg State Medical Institution City Multifunctional Hospital #2
  • Saint-Petersburg, Russian Federation, 195427
    • Russian Research Institute of Traumatology and Orthopaedics n.a.R.R.Vreden
  • Samara, Russian Federation, 443095
    • State Healthcare Institution Samara Regional Clinical Hospital named after V.D.Seredavin
  • Yaroslavl, Russian Federation, 150003
    • Clinical Emergency Hospital n.a. N.V. Solovyev
• Spain
  • Badalona, Spain, 08916
    • Hosp. Univ. Germans Trias I Pujol
  • Madrid, Spain, 28040
    • Hosp. Clinico San Carlos
  • Madrid, Spain, 28040
    • Hosp. Univ. Fund. Jimenez Diaz
  • Madrid, Spain, 28041
    • Hosp. Univ. 12 de Octubre
  • Madrid, Spain, 28046
    • Hosp. Univ. La Paz
  • Sabadell, Spain, 08208
    • Corporacio Sanitari Parc Tauli
  • Santiago de Compostela, Spain, 15706
    • Hosp. Clinico Univ. de Santiago
  • Valencia, Spain, 46026
    • Hosp. Univ. I Politecni La Fe
• Turkey
  • Ankara, Turkey, 06100
    • Ankara Numune Research and Training Hospital
  • Ankara, Turkey, 06110
    • Dışkapı Yıldırım Beyazıd Training and Research Hospital
  • Ankara, Turkey, 06370
    • Yıldırım Beyazıt University Yenimahalle Training and Research Hospital
  • Ankara, Turkey, 06800
    • Yildirim Beyazit University Medical Faculty Ankara Atatürk Research and Training Hospital
  • Istanbul, Turkey, 34764
    • Ümraniye Training and Research Hospital
  • Istanbul, Turkey, 34147
    • Bakirkoy Training and Research Hospital
  • Izmir, Turkey, 35180
    • Izmir Tepecik Training and Research Hospital
• Ukraine
  • Cherkasy, Ukraine, 18009
    • Municipal Institution Cherkasy Regional Hospital of Cherkasy Regional Council
  • Ivano-Frankivsk, Ukraine, 76008
    • Ivano-Frankivsk Regional Clinical Hospital
  • Kharkiv, Ukraine, 61024
    • Institute of Spine and JointPathology named after Prof.Sytenko of NationalAcademy of MedicalSciences
  • Kharkiv, Ukraine, 61176
    • Municipal Institution of Health Care 'Kharkiv Regional Clinical Traumatology Hospital'
  • Kyiv, Ukraine, 04107
    • Kyiv Regional Clinical Hospital
  • Lviv-Vynnyky, Ukraine, 79495
    • Communal Institution of Lviv Regional Council 'Lypa Lviv Regional Hospital'
  • Vinnytsia, Ukraine, 21018
    • Vinnytsya Regional Clinical Hospital named after M.I.Pirogov
  • Zaporizhzhia, Ukraine, 69600
    • Zaporizhzhia Regional Clinical Hospital
• United States
  • Arizona
    • Phoenix, Arizona, United States, 85053
      • Arizona Research Center
  • California
    • Torrance, California, United States, 90509
      • Harbor-UCLA Medical Center
  • Colorado
    • Englewood, Colorado, United States, 80113
      • Denver Metro Orthopedics, PC
  • Florida
    • DeLand, Florida, United States, 32720
      • Florida Research Associates, LLC
    • Pensacola, Florida, United States, 32504
      • Avanza research
    • Tamarac, Florida, United States, 33321
      • University Orthopedic and Joint Replacement Center
  • Texas
    • Houston, Texas, United States, 77024
      • Memorial Hermann Memorial City Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 46 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Weight greater than or equal to (>=) 40 kg to less than or equal to (<=) 150 kilogram (kg)
• Medically appropriate for postoperative anticoagulant prophylaxis as determined by the investigator
• Has undergone an elective primary unilateral total knee replacement (TKR)
• Before randomization, a woman must not be of childbearing potential defined as postmenopausal (defined as no menses for 12 months without an alternative medical cause) and/ or permanently sterile (include hysterectomy, bilateral salpingectomy, bilateral tubal occlusion/ligation procedures, and bilateral oophorectomy)
• Contraceptive use by men should be consistent with local regulations regarding the use of contraceptive methods for participant participating in clinical studies

Exclusion Criteria:

• Any condition for which the use of apixaban is not recommended in the opinion of the investigator
• Bilateral, revision or unicompartmental procedure
• Known or suspected hypersensitivity or intolerance to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or any of the excipients of JNJ-64179375
• Unable to undergo venography
• Known previous deep vein thrombosis (DVT) in either lower extremity

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

11

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Part 1: Cohort 1 (0.3 mg/kg JNJ-64179375/Apixaban); Participants will receive JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenously (IV) or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.	Drug: JNJ-64179375 0.3 mg/kg; JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion as a single dose on Day 1.; Drug: Placebo JNJ-64179375; Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.; Drug: Apixaban placebo; Matching apixaban placebo administered orally twice a day for 10 to 14 days.; Drug: Apixaban 2.5 mg; Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.
Experimental: Part 1: Cohort 2 (0.6 mg/kg JNJ-64179375/Apixaban); Participants will receive JNJ-64179375 0.6 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.	Drug: Placebo JNJ-64179375; Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.; Drug: Apixaban placebo; Matching apixaban placebo administered orally twice a day for 10 to 14 days.; Drug: Apixaban 2.5 mg; Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.; Drug: JNJ-64179375 0.6 mg/kg; JNJ-64179375 0.6 mg/kg IV infusion as a single dose on Day 1.
Experimental: Part 1: Cohort 3 (1.2 mg/kg JNJ-64179375/Apixaban); Participants will receive JNJ-64179375 1.2 mg/kg IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.	Drug: Placebo JNJ-64179375; Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.; Drug: Apixaban placebo; Matching apixaban placebo administered orally twice a day for 10 to 14 days.; Drug: Apixaban 2.5 mg; Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.; Drug: JNJ-64179375 1.2 mg/kg; JNJ-64179375 1.2 mg/kg IV infusion as a single dose on Day 1.
Experimental: Part 1: Optional Cohort 4 (JNJ-64179375/Apixaban); Participants will receive JNJ-64179375 Dose to be determined (TBD) based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.	Drug: Placebo JNJ-64179375; Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.; Drug: Apixaban placebo; Matching apixaban placebo administered orally twice a day for 10 to 14 days.; Drug: Apixaban 2.5 mg; Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.; Drug: JNJ-64179375 (Dose to be Determined); JNJ-64179375 IV infusion (Dose to be determined) as a single dose on Day 1.
Experimental: Part 1: Optional Cohort 5 (JNJ-64179375/Apixaban); Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.	Drug: Placebo JNJ-64179375; Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.; Drug: Apixaban placebo; Matching apixaban placebo administered orally twice a day for 10 to 14 days.; Drug: Apixaban 2.5 mg; Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.; Drug: JNJ-64179375 (Dose to be Determined); JNJ-64179375 IV infusion (Dose to be determined) as a single dose on Day 1.
Experimental: Part 1: Optional Cohort 6 (JNJ-64179375/Apixaban); Participants will receive JNJ-64179375 Dose TBD based on preliminary data (dose may range from 0.1 to 1.8 mg/kg or any dose from the preceding cohorts) IV or JNJ-64179375 placebo (saline) IV infusion as a single dose on Day 1 and matching apixaban placebo or 2.5 mg apixaban, orally twice a day for 10 to 14 days.	Drug: Placebo JNJ-64179375; Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.; Drug: Apixaban placebo; Matching apixaban placebo administered orally twice a day for 10 to 14 days.; Drug: Apixaban 2.5 mg; Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.; Drug: JNJ-64179375 (Dose to be Determined); JNJ-64179375 IV infusion (Dose to be determined) as a single dose on Day 1.
Experimental: Part 2: Group A: JNJ-64179375 A mg/kg and apixaban placebo; Participants will receive JNJ-64179375 Dose A mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.	Drug: Apixaban placebo; Matching apixaban placebo administered orally twice a day for 10 to 14 days.; Drug: JNJ-64179375 A mg/kg; JNJ-64179375 Dose A mg/kg IV as a single dose on Day 1.
Experimental: Part 2: Group B: JNJ-64179375 B mg/kg and apixaban placebo; Participants will receive JNJ-64179375 Dose B mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.	Drug: Apixaban placebo; Matching apixaban placebo administered orally twice a day for 10 to 14 days.; Drug: JNJ-64179375 B mg/kg; JNJ-64179375 Dose B mg/kg IV as a single dose on Day 1.
Experimental: Part 2: Group C: JNJ-64179375 C mg/kg and apixaban placebo; Participants will receive JNJ-64179375 Dose C mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.	Drug: Apixaban placebo; Matching apixaban placebo administered orally twice a day for 10 to 14 days.; Drug: JNJ-64179375 C mg/kg; JNJ-64179375 Dose C mg/kg IV as a single dose on Day 1.
Experimental: Part 2: Group D: JNJ-64179375 D mg/kg and apixaban placebo; Participants will receive JNJ-64179375 Dose D mg/kg (TBD based on review of data from Part 1) IV as a single dose on Day 1 and apixaban placebo orally twice a day for 10 to 14 days.	Drug: Apixaban placebo; Matching apixaban placebo administered orally twice a day for 10 to 14 days.; Drug: JNJ-64179375 D mg/kg; JNJ-64179375 Dose D mg/kg IV as a single dose on Day 1.
Experimental: Part 2: Group E: JNJ-64179375 placebo IV and apixaban 2.5 mg; Participants will receive JNJ-64179375 placebo (saline) IV as a single dose on Day 1 and apixaban 2.5 mg orally twice a day for 10 to 14 days.	Drug: Placebo JNJ-64179375; Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.; Drug: Apixaban 2.5 mg; Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Treatment-emergent Bleeding Events (Clinical Events Committee [CEC]- Adjudicated)	Number of participants with treatment-emergent bleeding events (BE) (adjudicated by CEC) were reported. Bleeding event was defined as the composite of major, clinically relevant nonmajor (CRNM), and minimal bleeding events assessed through the Day 10 to 14.	Up to Day 10 to 14 (visit observation period)
Number of Participants With Total Venous Thromboembolism (VTE) (CEC-adjudicated)	Number of participants with total VTE were reported. Total VTE was defined as the composite of CEC-adjudicated proximal and/or distal deep vein thrombosis (DVT) (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal pulmonary embolism (PE), or any death assessed through the Day 10 to 14 visit. 1 participant had an asymptomatic distal clot in the non-operated leg which is not counted in the Total VTE and 2 participants had symptomatic proximal clots at the Day 10 to 14 venography and are counted in both the asymptomatic proximal and symptomatic proximal groups.	Up to Day 10 to 14 (visit observation period)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With Composite of Major and CRNM Bleeding Events (CEC-adjudicated)	Number of participants with composite of major and CRNM bleeding events (adjudicated by CEC) were reported. Major Bleeding: Fatal bleeding; Bleeding that is symptomatic and occurs in critical area/organ and/or; Extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; Surgical site bleeding that requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; Surgical site bleeding that is unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE and meets at least 1 of following criteria: Epistaxis, Gastrointestinal bleed, Hematuria, Bruising/ecchymosis, Hemoptysis, Hematoma.	Up to Day 10 to 14 (visit observation period)
Number of Participants With Major Bleeding Event (CEC-adjudicated)	Number of participants with major bleeding events (BE) (adjudicated by CEC) were reported. Major Bleeding: Fatal bleeding; Bleeding that is symptomatic and occurs in critical area/organ and/or; Extrasurgical site bleeding causing fall in hemoglobin (Hb) level of 20 grams per liter (g/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; Surgical site bleeding that requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; Surgical site bleeding that is unexpected and prolonged and/or sufficiently large to cause hemodynamic instability.	Up to Day 10 to 14 (visit observation period)
Number of Participants With Clinically Relevant Non-major (CRNM) Bleeding Events (CEC-adjudicated)	Number of participants with CRNM bleeding events (adjudicated by CEC) were reported. CRNM bleeding was defined as acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major bleeding event and meets at least 1 of following criteria: Epistaxis, Gastrointestinal bleed, Hematuria, Bruising/ecchymosis, Hemoptysis, Hematoma.	Up to Day 10 to 14 (visit observation period)
Number of Participants With Major Bleeding or CRNM Bleeding Events (CEC-adjudicated)	Number of participants with major bleeding or CRNM bleeding events (adjudicated by CEC) were reported. Major Bleeding: Fatal bleeding; Bleeding that is symptomatic and occurs in critical area/organ and/or; Extrasurgical site bleeding causing fall in Hb level of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells with temporal association within 24-48 hours to bleeding, and/or; Surgical site bleeding that requires second intervention open, arthroscopic, endovascular, or hemarthrosis resulting in prolonged hospitalization or a deep wound infection and/or; Surgical site bleeding that is unexpected and prolonged and/or sufficiently large to cause hemodynamic instability. CRNM bleeding: acute clinically overt bleeding that does not satisfy additional criteria required for bleeding event to be defined as major BE and meets at least 1 of following criteria: Epistaxis, Gastrointestinal bleed, Hematuria, Bruising/ecchymosis, Hemoptysis, Hematoma.	Up to Day 10 and 14 (visit observation period)
Number of Participants With Minimal Bleeding Events (CEC-adjudicated)	Number of participants with minimal bleeding events (adjudicated by CEC) were reported. Minimal bleeding event was defined as any bleeding event not met major or CRNM criteria.	Up to Day 10 to 14 (visit observation period)
Number of Participants With Major VTE (CEC-adjudicated)	Number of participants with major VTE (adjudicated by CEC) were reported. Major VTE was defined as a composite of proximal DVT (asymptomatic confirmed by venography or objectively confirmed symptomatic), nonfatal PE, or any death. 2 participants had symptomatic proximal clots at the Day 10 to 14 venography and are counted in both the asymptomatic proximal and symptomatic proximal groups.	Up to Day 10 to 14 (visit observation period)
Number of Participants With Proximal Deep Vein Thrombosis (DVT) (CEC-adjudicated)	Number of participants with proximal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. 2 participants had symptomatic proximal clots at the Day 10 to 14 venography and are counted in both the asymptomatic proximal and symptomatic proximal groups.	Up to Day 10 to 14 (visit observation period)
Number of Participants With Nonfatal Pulmonary Embolism (PE) (CEC-adjudicated)	Number of participants with nonfatal PE (adjudicated by CEC) were reported.	Up to Day 10 to 14 (visit observation period)
Number of Participants With Death (CEC-adjudicated)	Number of participants with death (adjudicated by CEC) were reported.	Up to Day 10 to 14 (visit observation period)
Number of Participants With Proximal and Distal DVT (CEC-adjudicated)	Number of participants with proximal and distal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic. 2 participants had symptomatic proximal clots at the Day 10 to 14 venography and are counted in both the asymptomatic proximal and symptomatic proximal groups.	Up to Day 10 to 14 (visit observation period)
Number of Participants With Distal DVT (CEC-adjudicated)	Number of participants with distal DVT (adjudicated by CEC) were reported. DVT asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic.	Up to Day 10 to 14 (visit observation period)

Collaborators and Investigators

• Sponsor: Janssen Research & Development, LLC
• Investigators: Study Director: Janssen Research Development, LLC Clinical Trial, Janssen Research & Development, LLC

Study record dates

Study Major Dates

• Study Start (Actual): November 13, 2017
• Primary Completion (Actual): November 5, 2018
• Study Completion (Actual): November 5, 2018

Study Registration Dates

• First Submitted: August 14, 2017
• First Submitted That Met QC Criteria: August 14, 2017
• First Posted (Actual): August 16, 2017

Study Record Updates

• Last Update Posted (Actual): November 25, 2019
• Last Update Submitted That Met QC Criteria: November 5, 2019
• Last Verified: November 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protease Inhibitors; Factor Xa Inhibitors; Antithrombins; Serine Proteinase Inhibitors; Anticoagulants; Apixaban
• Other Study ID Numbers: CR108344; 2016-004550-15 (EudraCT Number); 64179375THR2001 (Other Identifier: Janssen Research & Development, LLC)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes